BioScience Health Innovations Amends Offering, Raises Price to $4.50/Share for $5.0M Capital Raise
BHIC has more than doubled off its 52-week low of $0.52 on light trading volume (0.1× avg).
Summary
BioScience Health Innovations has amended its Regulation A offering, raising the share price from $1.00 to $4.50 and aiming to raise an additional $5.0 million, providing critical capital for operations and growth.
Key Events · Financing and Capital Events · BHIC
-
Offering Price Increased Significantly
The offering price for common shares has been increased from $1.00 to $4.50 per share, a substantial premium to the previous offering terms and the recent market price of $4.18 (June 16, 2026).
-
Substantial Capital Raise
The company aims to sell an additional 1,111,111 shares at $4.50, targeting $5.0 million in new proceeds. This represents a significant capital raise for the company.
-
Dilution for Existing Shareholders
The offering of 1,111,111 new shares represents approximately 9.48% dilution to existing shareholders based on 11,714,004 shares outstanding as of June 9, 2026.
-
Provides Critical Working Capital
The proceeds will be used for advertising, marketing, compensation, legal, IT, and general working capital, addressing the company's Q1 net loss and negative operating cash flow.
Analysis · BHIC · Technology
This filing amends a previous Regulation A offering, significantly increasing the offering price from $1.00 to $4.50 per share and the number of shares to be sold. This repricing, at a premium to the recent market price, indicates strong investor interest and provides BioScience Health Innovations with a crucial $5.0 million capital infusion. This funding is vital for the company, which recently reported a Q1 net loss and negative operating cash flow, extending its financial runway and supporting its growth initiatives, including a potential uplisting to a senior exchange.
At the time of this filing, BHIC was trading at $4.50 on OTC in the Technology sector, with a market capitalization of approximately $51.4M. The 52-week trading range was $0.52 to $72.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.